Stock Ratings / Health Care / OCGN / earnings

LXEO (36) FATE (40) LCTX (29) IPSC (28) ⌘ Pro Terminal →

Ocugen Inc. (OCGN) Next Earnings Date & Expected ±12.5% Move

Q: When is OCGN's next earnings date?

Based on SEC filing cadence, Ocugen Inc. (OCGN)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is OCGN stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for OCGN, spanning a range between $1 and $0.83.

$0.74 -4.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Ocugen Inc. (OCGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $252.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OCGN)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.09 Expected Swing

MODEL EARNINGS SETUP GAUGE

OCGN Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: 8.8%

Model Bullish Setup (35/100)Model Risk Weight (65/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$4.4M	-$68.0M	-$57.1M	52%
FY 2024	2024-12-31	$4.1M	-$54.0M	-$45.5M	52%
FY 2023	2023-12-31	$6.0M	-$63.0M	-$62.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OCGN)

✓Walkthrough of OCGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OCGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.23%▼ SUPPORT BREAKDOWN

2026-10-30O $0.75H $0.76L $0.69C $0.74VOL 5.41M

RES: $1.20SUP: $0.78SMA50: $1.03SMA200: $1.43

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OCGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OCGN Butterfly Map → + Track OCGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OCGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OCGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OCGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OCGN)

Health Care Rank #818 of 1016 ⚔️ LXEO vs OCGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OCGN vs. LXEO, FATE, LCTX, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ocugen Inc. (OCGN) ranks #818 by composite RQD confidence (35/100, grade D-) and #546 by equity capitalization ($252.4M). Within this direct 5-issuer industry benchmark cohort, OCGN leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with OCGN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OCGN ACTIVE Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	Benchmark Subject
LXEO Lexeo Therapeutics Inc.	D-	36/100	—	—	-35.0%	-2.24%	$251.1M	/lxeo-vs-ocgn →
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-ocgn →
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-ocgn →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-ocgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001372299

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ocugen Inc. (OCGN) reported GAAP revenue of $4.4M (+8.8% vs. FY2024 revenue of $4.1M , and -26.9% cumulative change since FY2023) , GAAP net income of -$68.0M, operating cash flow of -$57.0M, and free cash flow of -$57.1M (-25.5% YoY). On the balance sheet, OCGN closed FY2025 with $43.5M in total assets against $27.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.4M	-$68.0M	-$57.0M	-$57.1M	$43.5M	$27.5M
FY2024 (FY)	2024-12-31	$4.1M	-$54.0M	-$42.1M	-$45.5M	$82.4M	$27.3M
FY2023 (FY)	2023-12-31	$6.0M	-$63.0M	-$62.1M	-$62.1M	—	—

3. OCGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OCGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Ocugen Inc. (NASDAQ: OCGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.74 (-4.15% 1D, market cap $252.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OCGN ranks #818 in composite RQD confidence.

How does OCGN compare to LXEO and FATE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OCGN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $251.1M) and FATE (Fate Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $260.0M). Among the 5-stock peer group, OCGN leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OCGN?

Per OCGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372299), Ocugen Inc. generated $4.4M in revenue (+8.8% YoY), -$68.0M in net income, and -$57.1M in free cash flow against $43.5M in total assets and $27.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OCGN trading relative to its 50-day, 200-day, and 52-week technical levels?

OCGN last traded at $0.74 (-4.15% on volume of 5,534,074 shares), positioning the stock -28.16% below its 50-day simple moving average ($1.03) and -48.25% below its 200-day simple moving average ($1.43). Across its 52-week range of $0.69 to $2.73, OCGN sits at the 2.5% percentile with a 14-day RSI of 28.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.83).